What is the current valuation of the Mitral Valve Stenosis Market as of 2024?

The Mitral Valve Stenosis Market was valued at 2728.44 USD Million in 2024. Read More

What is the projected market size for the Mitral Valve Stenosis Market in 2035?

The market is projected to reach 6852.39 USD Million by 2035. Read More

What is the expected CAGR for the Mitral Valve Stenosis Market during the forecast period 2025 - 2035?

The expected CAGR for the Mitral Valve Stenosis Market during 2025 - 2035 is 8.69%. Read More

Which companies are considered key players in the Mitral Valve Stenosis Market?

Key players include Abbott, Medtronic, Boston Scientific, Edwards Lifesciences, and Janssen Pharmaceuticals. Read More

What are the main types of Mitral Valve Stenosis and their market valuations?

Rheumatic, Congenital, Degenerative, and Functional Mitral Valve Stenosis have valuations ranging from 528.44 to 2000.0 USD Million. Read More

What diagnostic methods are used in the Mitral Valve Stenosis Market and their respective valuations?

Echocardiography, Cardiac Catheterization, Electrocardiogram, and Chest X-ray have valuations from 409.75 to 2710.0 USD Million. Read More

What treatment approaches are available for Mitral Valve Stenosis and their market sizes?

Surgical Intervention, Percutaneous Mitral Balloon Valvotomy, Medications, and Transcatheter Mitral Valve Replacement range from 500.0 to 2152.39 USD Million. Read More

How do patient demographics influence the Mitral Valve Stenosis Market?

Factors such as Age Group, Gender, Comorbidities, and Lifestyle Factors have valuations between 500.0 and 2152.39 USD Million. Read More

What segment is expected to show the highest growth in the Mitral Valve Stenosis Market?

The segment of Comorbidities is likely to show substantial growth, with a valuation of 2000.0 USD Million. Read More

How does the Mitral Valve Stenosis Market compare to other cardiovascular markets?

The Mitral Valve Stenosis Market appears to be growing steadily, with a projected increase in valuation indicating robust demand. Read More

Mitral Valve Stenosis Market

ID: MRFR/MED/5098-CR

100 Pages

Rahul Gotadki

Last Updated: June 26, 2026

Mitral Valve (Stenosis & Regurgitation) Treatment Market Research Report by Pathological Condition (Mitral Stenosis, Mitral Regurgitation), by Etiology (Rheumatic mitral stenosis, Calcified (non-rheumatic) mitral stenosis), by Treatment (Surgery, Medications)- Forecast till 2035

Mitral Valve Stenosis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.48%

2024 Market Size$ 6,750.71 Million

2025 Market Size$ 7,323.17 Million

2035 Market Size$ 16,527.07 Million

Key Players

Abbott

Bayer AG

Edwards Lifesciences Corporation

Artivion, Inc.

Medtronic

Novartis AG

Trends

Disease Prevalence Drives Treatment Demand
Awareness Campaigns Boost Market Outlook

Opportunities

Demographic Pressures
Patient-Centric Shifts
Rising Disease Prevalence

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Mitral Valve Stenosis (USD Million) | |
  1. 4.1.1 Rheumatic Mitral Valve Stenosis | |
  2. 4.1.2 Congenital Mitral Valve Stenosis | |
  3. 4.1.3 Degenerative Mitral Valve Stenosis | |
  4. 4.1.4 Functional Mitral Valve Stenosis |
2. 4.2 Healthcare, BY Diagnosis Method (USD Million) | |
  1. 4.2.1 Echocardiography | |
  2. 4.2.2 Cardiac Catheterization | |
  3. 4.2.3 Electrocardiogram | |
  4. 4.2.4 Chest X-ray |
3. 4.3 Healthcare, BY Treatment Approach (USD Million) | |
  1. 4.3.1 Surgical Intervention | |
  2. 4.3.2 Percutaneous Mitral Balloon Valvotomy | |
  3. 4.3.3 Medications | |
  4. 4.3.4 Transcatheter Mitral Valve Replacement |
4. 4.4 Healthcare, BY Patient Demographics (USD Million) | |
  1. 4.4.1 Age Group | |
  2. 4.4.2 Gender | |
  3. 4.4.3 Comorbidities | |
  4. 4.4.4 Lifestyle Factors |
5. 4.5 Healthcare, BY Region (USD Million) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Abbott (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Medtronic (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boston Scientific (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Edwards Lifesciences (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Janssen Pharmaceuticals (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Baxter International (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sorin Group (IT) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 LivaNova (GB) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Terumo Corporation (JP) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
7. 6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD |
8. 6.5 US MARKET ANALYSIS BY TREATMENT APPROACH |
9. 6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
11. 6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD |
12. 6.9 CANADA MARKET ANALYSIS BY TREATMENT APPROACH |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
16. 6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD |
17. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT APPROACH |
18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
19. 6.16 UK MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
20. 6.17 UK MARKET ANALYSIS BY DIAGNOSIS METHOD |
21. 6.18 UK MARKET ANALYSIS BY TREATMENT APPROACH |
22. 6.19 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
24. 6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD |
25. 6.22 FRANCE MARKET ANALYSIS BY TREATMENT APPROACH |
26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
28. 6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
29. 6.26 RUSSIA MARKET ANALYSIS BY TREATMENT APPROACH |
30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
32. 6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD |
33. 6.30 ITALY MARKET ANALYSIS BY TREATMENT APPROACH |
34. 6.31 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
36. 6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD |
37. 6.34 SPAIN MARKET ANALYSIS BY TREATMENT APPROACH |
38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY TREATMENT APPROACH |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
45. 6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
46. 6.43 CHINA MARKET ANALYSIS BY TREATMENT APPROACH |
47. 6.44 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
49. 6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
50. 6.47 INDIA MARKET ANALYSIS BY TREATMENT APPROACH |
51. 6.48 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
53. 6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD |
54. 6.51 JAPAN MARKET ANALYSIS BY TREATMENT APPROACH |
55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY TREATMENT APPROACH |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
61. 6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
62. 6.59 MALAYSIA MARKET ANALYSIS BY TREATMENT APPROACH |
63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
65. 6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD |
66. 6.63 THAILAND MARKET ANALYSIS BY TREATMENT APPROACH |
67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
69. 6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD |
70. 6.67 INDONESIA MARKET ANALYSIS BY TREATMENT APPROACH |
71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
73. 6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD |
74. 6.71 REST OF APAC MARKET ANALYSIS BY TREATMENT APPROACH |
75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
78. 6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD |
79. 6.76 BRAZIL MARKET ANALYSIS BY TREATMENT APPROACH |
80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
82. 6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD |
83. 6.80 MEXICO MARKET ANALYSIS BY TREATMENT APPROACH |
84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
86. 6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD |
87. 6.84 ARGENTINA MARKET ANALYSIS BY TREATMENT APPROACH |
88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT APPROACH |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT APPROACH |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT APPROACH |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF MITRAL VALVE STENOSIS |
103. 6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD |
104. 6.101 REST OF MEA MARKET ANALYSIS BY TREATMENT APPROACH |
105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE OF MITRAL VALVE STENOSIS, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE OF MITRAL VALVE STENOSIS, 2024 TO 2035 (USD Million) |
114. 6.111 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million) |
116. 6.113 HEALTHCARE, BY TREATMENT APPROACH, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY TREATMENT APPROACH, 2024 TO 2035 (USD Million) |
118. 6.115 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.2.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.3.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.3.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.3.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.4.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.4.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.4.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.5.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.5.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.5.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.6.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.6.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.6.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.7.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.7.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.7.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.8.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.8.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.8.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.9.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.9.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.9.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.10.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.10.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.10.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.11.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.11.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.11.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.12.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.12.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.12.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.13.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.13.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.13.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.14.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.14.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.14.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.15.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.15.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.15.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.16.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.16.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.16.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.17.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.17.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.17.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.18.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.18.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.18.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.19.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.19.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.19.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.20.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.20.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.20.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.21.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.21.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.21.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.22.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.22.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.22.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.23.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.23.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.23.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.24.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.24.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.24.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.25.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.25.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.25.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.26.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.26.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.26.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.27.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.27.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.27.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.28.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.28.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.28.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.29.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.29.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.29.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF MITRAL VALVE STENOSIS, 2025-2035 (USD Million) | |
  2. 7.30.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.30.3 BY TREATMENT APPROACH, 2025-2035 (USD Million) | |
  4. 7.30.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Mitral Valve Stenosis Market Segmentation

Mitral Valve Stenosis Market By Type of Mitral Valve Stenosis (USD Million, 2025-2035)

Rheumatic Mitral Valve Stenosis
Congenital Mitral Valve Stenosis
Degenerative Mitral Valve Stenosis
Functional Mitral Valve Stenosis

Mitral Valve Stenosis Market By Diagnosis Method (USD Million, 2025-2035)

Echocardiography
Cardiac Catheterization
Electrocardiogram
Chest X-ray

Mitral Valve Stenosis Market By Treatment Approach (USD Million, 2025-2035)

Surgical Intervention
Percutaneous Mitral Balloon Valvotomy
Medications
Transcatheter Mitral Valve Replacement

Mitral Valve Stenosis Market By Patient Demographics (USD Million, 2025-2035)

Age Group
Gender
Comorbidities
Lifestyle Factors

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”